Details of the Drug

General Information of Drug (ID: DM5D7VG)

Drug Name
Pegozafermin
Synonyms BIO89-100
Indication
Disease Entry ICD 11 Status REF
Hypertriglyceridemia 5C80.1 Phase 3 [1]
Cross-matching ID
TTD ID
DZ2B3I

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-21 (FGF21) TTQ916P FGF21_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertriglyceridemia
ICD Disease Classification 5C80.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor-21 (FGF21) DTT FGF21 9.68E-01 0.05 0.22
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05852431) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study. U.S.National Institutes of Health.
2 Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132.